一项旨在系统地增强健康成年人的认知储备的新计划:试点随机主控临床试验
Carol Kotliar1,2, Lisandro Olmos1,3, Martín Koretzky1
1Espacio Santa María, Buenos Aires, Argentina.
PloS one
|October 1, 2025
概括
心理训练技术24.5 (MTT24.5) 计划显著改善了健康成年人的认知功能和记忆. 这种认知刺激可能有助于预防与年龄相关的认知衰退.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 老年学是一门学科.
背景情况:
- 认知能力下降是老年人群日益关注的一个问题.
- 神经可塑性和认知储备可以通过有针对性的认知训练来增强.
- 心理训练技术 24.5 (MTT24.5) 计划使用一种系统算法,将知识获取 (DATA) 和学习技术 (TECHS) 结合起来,以刺激大脑功能.
研究的目的:
- 为了评估MTT24.5认知刺激计划的有效性.
- 评估该计划对健康成年人的认知表现和神经可塑性的影响.
主要方法:
- 试点临床研究,主动对照和开放随机化.
- 招募了120名志愿者;76名参与者 (56名干预,20名控制) 完成了这项研究.
- MTT24.5计划包括12个每周的会议 (24.5小时),重点是40个知识单元和100个学习技巧.
- 认知评估包括ACE-R和MMSE,以及干预前后评估.
主要成果:
- 与对照组 (p < 0.001) 相比,干预组的整体认知得分显著增加 (4.6分,5%).
- 干预组的记忆域得分显著改善 (2.4分,11.4%的增加) (p < 0.007).
- 在口头流利,语言和视觉空间技能方面也有所改善,特别是在基线ACE-R得分较低的参与者中 (p < 0.003).
结论:
- MTT24.5计划有效地提高了认知储备和表现,特别是在基线认知得分较低的个体中.
- 结构化认知刺激可能在预防认知衰退和促进健康成年人的认知健康方面发挥关键作用.
- 建议对较大群体进行进一步的研究和长期随访,以验证这些发现并探索更广泛的应用.
相关概念视频
01:30Cognitive Development During Adulthood
780
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
780
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144